VENUS CONCEPT INC VERO 深 滬
等待開盤 12-20 09:30:00 美东时间
1.90
+0.020
+1.06%
華盛通- 最 高2.07
- 今 開1.86
- 成交量 18.41万股
- 最 低 1.82
- 昨 收 1.88
- 總市值 353.23万
- 52周最高 14.50
- 市盈率 靜 --
- 換手率 9.90%
- 52周最低 1.65
- 委 比 -85.71%
- 總股本 185.91万
- 歷史最高 29576.25
- 量 比 0.02
- 振 幅 13.30%
- 歷史最低 1.82
- 每 手 1
- 風險率 0.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 38.7% to...
12-16 20:05
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
Shares of B Riley Financial Inc (NASDAQ:RILY) rose sharply in pre-market tradin...
12-16 18:53
Venus Concept Amends Loan Agreement with Madryn Health
Venus Concept ( ($VERO) ) has issued an announcement. On November 30, 2025, Ven...
12-03 05:51
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
11-13 19:11
Venus Concept Receives 510(k) for the Venus NOVA, Its Most Advanced Multi-Application Platform for Non-Invasive Body and Skin Treatments
Venus Concept Inc. announced the FDA clearance for Venus NOVA™, a next-generation aesthetic platform, marking the first product under their new R&D strategy. The device integrates EMS, (MP)², and Advanced VariPulse™ for comprehensive body contouring, muscle conditioning, and skin treatments. Equipped with IoT connectivity via Venus Connect™, it offers real-time analytics and system optimization for clinics. Venus NOVA will launch in the U.S. in D...
11-10 12:30
Venus Concept Enters Consent Agreement with Madryn Health
The latest announcement is out from Venus Concept ( ($VERO) ). On October 31, 2...
11-01 05:49
EyePoint Pharmaceuticals Initiates Pivotal Phase 3 Program For DURAVYU To Treat Diabetic Macular Edema; Expects First Patient Dosage In Q1 2026
WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with
10-15 04:03
Venus Concept Reduces Debt with Equity Exchange
The latest update is out from Venus Concept ( ($VERO) ). On September 30, 2025,...
10-03 04:28
Venus Concept announces $11.48 million debt-to-equity exchange transaction
Venus Concept (NASDAQ:VERO) announced on Thursday the company exchanged the full $11.48 million balance of its subordinated convertible notes held by affiliates of Madryn Asset Management for 545,335 ...
10-03 04:17
Venus Concept Exchanged The Full $11.48M Balance Of Its Subordinated Convertible Notes Held By Affiliates Of Madryn Asset Management For 545,335 Shares Of Its Series Y Preferred Stock; Co Had Total Debt Obligations Of ~$30.1M, A Reduction Of 24% Compared To $39.7M Outstanding As Of December 31, 2024
Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that, on September 30, 2025, the Company exchanged the full $11.48 million balance of its
10-03 04:09
